EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Azathioprine‐induced vanishing bile duct syndrome: The value of early thiopurine metabolism assessment

Laurent Chouchana iD, Benoit Terris iD, Philippe Sogni iD, Jean-Marc Treluyer iD, Nathalie Costedoat-Chalumeau iD, Marie-Anne Loriot iD

British Journal of Clinical Pharmacology · 2023-08 · 89 (8) · 2625-2630

DOI: 10.1111/bcp.15797 ↗

Kurz gefasst

Fallbericht in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 06.06.2023. Verfasst von Laurent Chouchana und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre Régional de Pharmacovigilance, Service de Pharmacologie périnatale, pédiatrique et adulte, Hôpital Cochin, AP-HP.Centre, Université Paris Cité…. Hauptthemen laut MEDLINE: Azathioprine, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

About 15% to 28% of patients treated with thiopurines experienced adverse drug reactions, such as haematological and hepatic toxicities. Some of these related to the polymorphic activity of the thiopurine S‐methyltransferase (TPMT), the key detoxifying enzyme of thiopurine metabolism. We report here a case of thiopurine‐induced ductopenia with a comprehensive pharmacological analysis on thiopurine metabolism. A 34‐year‐old woman, with a medical history of severe systemic lupus erythematosus with recent introduction of azathioprine therapy, presented with mild fluctuating transaminase blood levels consistent with a hepatocellular pattern, which evolved to a cholestatic pattern over the next weeks. A blood thiopurine metabolite assay revealed low 6‐thioguanine nucleotides (6‐TGN) level and a dramatically increased 6‐methylmercaptopurine ribonucleotides (6‐MMPN) level, together with an unfavourable [6‐MMPN:6‐TGN] metabolite ratio and a high TPMT activity. After a total of about 6 months of thiopurine therapy, a transjugular liver biopsy revealed a ductopenia, and azathioprine discontinuation led to further clinical improvement. In line with previous reports from the literature, our case supports the fact that ductopenia is a rare adverse drug reaction of azathioprine. The mechanism of reaction is unknown but may involve high 6‐MMPN blood level, due to unusual thiopurine metabolism (switched metabolism). Early therapeutic drug monitoring with measurement of 6‐TGN and 6‐MMPN blood levels may help physicians to identify patients at risk of similar duct injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzathioprineLupus Erythematosus, SystemicFemaleHumansAdultImmunosuppressive AgentsThioguanineThionucleotidesMethyltransferasesBile DuctsMercaptopurineGuanine Nucleotides

Stichwörter der Autor:innen

ductopeniahepatitispharmacogenomicspharmacovigilancethiopurinevanishing bile duct syndrome

Substanzen

AzathioprineImmunosuppressive AgentsThioguanineThionucleotidesMethyltransferasesMercaptopurineGuanine Nucleotides

Autor:innen und Institutionen

  • Centre Régional de Pharmacovigilance, Service de Pharmacologie périnatale, pédiatrique et adulte, Hôpital Cochin, AP-HP.Centre, Université Paris Cité, Paris, France.
  • Service de Pathologie, Hôpital Cochin, AP-HP.Centre, Université Paris Cité, Paris, France.
  • Service d'hépatologie, Hôpital Cochin, AP-HP.Centre, Université Paris Cité, Paris, France.
  • Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Département de Médecine interne, Hôpital Cochin, AP-HP.Centre, Université Paris Cité, Paris, France.
  • INSERM U 1153, Center for Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris, France.
  • Unité de Pharmacogénétique, Service de Biochimie, Hôpital européen Georges Pompidou, AP-HP.Centre, Université Paris Cité, Paris, France.

ORCID-Profile: Laurent Chouchana, Benoit Terris, Philippe Sogni, Jean-Marc Treluyer, Nathalie Costedoat-Chalumeau, Marie-Anne Loriot

Zitieren

APA

Chouchana, L., Terris, B., Sogni, P., Treluyer, J. M., Costedoat-Chalumeau, N., & Loriot, M. A. (2023). Azathioprine‐induced vanishing bile duct syndrome: The value of early thiopurine metabolism assessment. British Journal of Clinical Pharmacology, 89(8), 2625-2630. https://doi.org/10.1111/bcp.15797

Vancouver

Chouchana L, Terris B, Sogni P, Treluyer JM, Costedoat-Chalumeau N, Loriot MA. Azathioprine‐induced vanishing bile duct syndrome: The value of early thiopurine metabolism assessment. British Journal of Clinical Pharmacology. 2023;89(8):2625-2630. doi:10.1111/bcp.15797

BibTeX
@article{Chouchana2023,
  author = {Chouchana, Laurent and Terris, Benoit and Sogni, Philippe and Treluyer, Jean-Marc and Costedoat-Chalumeau, Nathalie and Loriot, Marie-Anne},
  title = {Azathioprine‐induced vanishing bile duct syndrome: The value of early thiopurine metabolism assessment},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  volume = {89},
  number = {8},
  pages = {2625--2630},
  doi = {10.1111/bcp.15797}
}
Kostenlos starten →